Sagitta Biotech is developing a targeted therapy based on Oncolytic Viruses, which are vaccine strains modified to specifically kill tumor cells. Sagitta Biotech is building a vector that we hope is better than the competition, because we designed it to be targeted (it specifically infects cells carrying a tumor marker) and a viral genome that induces apoptosis as well as a local immune response.